Do not sell your shares until mid-2014. Sell after the FDA approves 809/Kalydeco for F508del mutation. The data presented yesterday are excellent. Some did not understand correctly, a bear pretended the data were bad, and other bears just followed the leader. Even good analysts and reporters interpreted the data incorrectly. Feuerstein is one and the Barclays is another. I will expand this point to post tomorrow.
For those who bought shares on Cramer's suggestion, I have to tell you that Cramer was correct. He was rather conservative in saying that the pps would double. It will more than double from here in two years. Cramer assumed that the drug price would be 200 K. To treat homozygous 508 patients, two drugs are needed, VX-809 and Kalydeco. Kalydeco alone costs almost 300 K now.
I am confident that you will double your investment in two years. Listen to yesterday's Vertex webcast. you will be convinced too.